Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor

Saved in:
Bibliographic Details
Published in:British journal of haematology 2020-09, Vol.190 (5), p.642-642
Main Authors: Yuan, Yin, Mapp, Sally, Xu, Wen
Format: Article
Language:English
Subjects:
Aged
Anaplastic Lymphoma Kinase - antagonists & inhibitors
Brain Neoplasms - drug therapy
Brain Neoplasms - metabolism
Brain Neoplasms - pathology
Carbazoles - administration & dosage
Carbazoles - adverse effects
Enzyme inhibitors
Erythrocytes - metabolism
Erythrocytes - pathology
Female
Hematology
Hemolysis - drug effects
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Male
Piperidines - administration & dosage
Piperidines - adverse effects
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Protein-tyrosine kinase
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3883-d58cad51eec07caf4f95f6447c8826c9c0f95a19f26bec1fd8e4f0417cd835763
cites
container_end_page 642
container_issue 5
container_start_page 642
container_title British journal of haematology
container_volume 190
creator Yuan, Yin
Mapp, Sally
Xu, Wen
description
doi_str_mv 10.1111/bjh.16813
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2441240125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2441240125</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-d58cad51eec07caf4f95f6447c8826c9c0f95a19f26bec1fd8e4f0417cd835763</originalsourceid><addsrcrecordid>eNp1kF1LwzAUhoMobk4v_AMS8EqwW06TttmlDj8ZeDOvS5omNFva1KZj9N-buemd4YSQcx7eAw9C10CmEM6sWFdTSDnQEzQGmiZRDAxO0ZgQkkVAGB-hC-_XhAAlCZyjEY0TmmWUj9FutXNYCq88dhrXotuoEnfhSmUtFo3xrnVmY6yTQ--88aFX4kqo2tlh_92ZvsLCKtmbxhT3YRxKtFb43khsh7qtXC3wxjRhCTZNZQrTu-4SnWlhvbo6vhP0-fy0WrxGy4-Xt8XDMpKUcxqVCZeiTEApSTIpNNPzRKeMZZLzOJVzSUJDwFzHaaEk6JIrpgmDTJacJllKJ-j2kNt27murfJ-v3bZrwso8ZgxiRiC4mKC7AyU7532ndN52JsgYciD5XnEeFOc_igN7c0zcFrUq_8hfpwGYHYCdsWr4Pyl_fH89RH4Dr3OHaw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2441240125</pqid></control><display><type>article</type><title>Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Yuan, Yin ; Mapp, Sally ; Xu, Wen</creator><creatorcontrib>Yuan, Yin ; Mapp, Sally ; Xu, Wen</creatorcontrib><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.16813</identifier><identifier>PMID: 32537738</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Aged ; Anaplastic Lymphoma Kinase - antagonists &amp; inhibitors ; Brain Neoplasms - drug therapy ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Carbazoles - administration &amp; dosage ; Carbazoles - adverse effects ; Enzyme inhibitors ; Erythrocytes - metabolism ; Erythrocytes - pathology ; Female ; Hematology ; Hemolysis - drug effects ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Lung Neoplasms - pathology ; Male ; Piperidines - administration &amp; dosage ; Piperidines - adverse effects ; Protein Kinase Inhibitors - administration &amp; dosage ; Protein Kinase Inhibitors - adverse effects ; Protein-tyrosine kinase</subject><ispartof>British journal of haematology, 2020-09, Vol.190 (5), p.642-642</ispartof><rights>2020 British Society for Haematology and John Wiley &amp; Sons Ltd</rights><rights>Copyright © 2020 John Wiley &amp; Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-d58cad51eec07caf4f95f6447c8826c9c0f95a19f26bec1fd8e4f0417cd835763</citedby><orcidid>0000-0002-9353-1702</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32537738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuan, Yin</creatorcontrib><creatorcontrib>Mapp, Sally</creatorcontrib><creatorcontrib>Xu, Wen</creatorcontrib><title>Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><subject>Aged</subject><subject>Anaplastic Lymphoma Kinase - antagonists &amp; inhibitors</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Carbazoles - administration &amp; dosage</subject><subject>Carbazoles - adverse effects</subject><subject>Enzyme inhibitors</subject><subject>Erythrocytes - metabolism</subject><subject>Erythrocytes - pathology</subject><subject>Female</subject><subject>Hematology</subject><subject>Hemolysis - drug effects</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Piperidines - administration &amp; dosage</subject><subject>Piperidines - adverse effects</subject><subject>Protein Kinase Inhibitors - administration &amp; dosage</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein-tyrosine kinase</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kF1LwzAUhoMobk4v_AMS8EqwW06TttmlDj8ZeDOvS5omNFva1KZj9N-buemd4YSQcx7eAw9C10CmEM6sWFdTSDnQEzQGmiZRDAxO0ZgQkkVAGB-hC-_XhAAlCZyjEY0TmmWUj9FutXNYCq88dhrXotuoEnfhSmUtFo3xrnVmY6yTQ--88aFX4kqo2tlh_92ZvsLCKtmbxhT3YRxKtFb43khsh7qtXC3wxjRhCTZNZQrTu-4SnWlhvbo6vhP0-fy0WrxGy4-Xt8XDMpKUcxqVCZeiTEApSTIpNNPzRKeMZZLzOJVzSUJDwFzHaaEk6JIrpgmDTJacJllKJ-j2kNt27murfJ-v3bZrwso8ZgxiRiC4mKC7AyU7532ndN52JsgYciD5XnEeFOc_igN7c0zcFrUq_8hfpwGYHYCdsWr4Pyl_fH89RH4Dr3OHaw</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Yuan, Yin</creator><creator>Mapp, Sally</creator><creator>Xu, Wen</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><orcidid>https://orcid.org/0000-0002-9353-1702</orcidid></search><sort><creationdate>202009</creationdate><title>Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor</title><author>Yuan, Yin ; Mapp, Sally ; Xu, Wen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-d58cad51eec07caf4f95f6447c8826c9c0f95a19f26bec1fd8e4f0417cd835763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Anaplastic Lymphoma Kinase - antagonists &amp; inhibitors</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Carbazoles - administration &amp; dosage</topic><topic>Carbazoles - adverse effects</topic><topic>Enzyme inhibitors</topic><topic>Erythrocytes - metabolism</topic><topic>Erythrocytes - pathology</topic><topic>Female</topic><topic>Hematology</topic><topic>Hemolysis - drug effects</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Piperidines - administration &amp; dosage</topic><topic>Piperidines - adverse effects</topic><topic>Protein Kinase Inhibitors - administration &amp; dosage</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein-tyrosine kinase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuan, Yin</creatorcontrib><creatorcontrib>Mapp, Sally</creatorcontrib><creatorcontrib>Xu, Wen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuan, Yin</au><au>Mapp, Sally</au><au>Xu, Wen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2020-09</date><risdate>2020</risdate><volume>190</volume><issue>5</issue><spage>642</spage><epage>642</epage><pages>642-642</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>32537738</pmid><doi>10.1111/bjh.16813</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-9353-1702</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1048
ispartof British journal of haematology, 2020-09, Vol.190 (5), p.642-642
issn 0007-1048
1365-2141
language eng
recordid cdi_proquest_journals_2441240125
source Wiley-Blackwell Read & Publish Collection
subjects Aged
Anaplastic Lymphoma Kinase - antagonists & inhibitors
Brain Neoplasms - drug therapy
Brain Neoplasms - metabolism
Brain Neoplasms - pathology
Carbazoles - administration & dosage
Carbazoles - adverse effects
Enzyme inhibitors
Erythrocytes - metabolism
Erythrocytes - pathology
Female
Hematology
Hemolysis - drug effects
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Male
Piperidines - administration & dosage
Piperidines - adverse effects
Protein Kinase Inhibitors - administration & dosage
Protein Kinase Inhibitors - adverse effects
Protein-tyrosine kinase
title Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A14%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Two%20cases%20of%20marked%20red%20cell%20anisopoikilocytosis%20and%20haemolysis%20with%20alectinib,%20an%20anaplastic%20lymphoma%20kinase%20inhibitor&rft.jtitle=British%20journal%20of%20haematology&rft.au=Yuan,%20Yin&rft.date=2020-09&rft.volume=190&rft.issue=5&rft.spage=642&rft.epage=642&rft.pages=642-642&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.16813&rft_dat=%3Cproquest_cross%3E2441240125%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3883-d58cad51eec07caf4f95f6447c8826c9c0f95a19f26bec1fd8e4f0417cd835763%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2441240125&rft_id=info:pmid/32537738&rfr_iscdi=true